GB0405634D0 - Anti-virus therapy for respiratory diseases - Google Patents

Anti-virus therapy for respiratory diseases

Info

Publication number
GB0405634D0
GB0405634D0 GBGB0405634.7A GB0405634A GB0405634D0 GB 0405634 D0 GB0405634 D0 GB 0405634D0 GB 0405634 A GB0405634 A GB 0405634A GB 0405634 D0 GB0405634 D0 GB 0405634D0
Authority
GB
United Kingdom
Prior art keywords
agent
respiratory diseases
virus therapy
treatment
rhinovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0405634.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southampton
Original Assignee
University of Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southampton filed Critical University of Southampton
Priority to GBGB0405634.7A priority Critical patent/GB0405634D0/en
Publication of GB0405634D0 publication Critical patent/GB0405634D0/en
Priority to HK07104017.4A priority patent/HK1097181B/en
Priority to CA2787978A priority patent/CA2787978A1/en
Priority to PCT/GB2005/050031 priority patent/WO2005087253A2/en
Priority to CA2558212A priority patent/CA2558212C/en
Priority to AT05708482T priority patent/ATE466591T1/de
Priority to EP05708482A priority patent/EP1734987B1/en
Priority to DE602005021078T priority patent/DE602005021078D1/de
Priority to JP2007502414A priority patent/JP4807526B2/ja
Priority to ES05708482T priority patent/ES2343732T3/es
Priority to PT05708482T priority patent/PT1734987E/pt
Priority to EP10161661A priority patent/EP2206512A3/en
Priority to DK05708482.4T priority patent/DK1734987T3/da
Priority to PL05708482T priority patent/PL1734987T3/pl
Priority to US11/517,763 priority patent/US7569216B2/en
Priority to US12/487,563 priority patent/US8273342B2/en
Priority to JP2011093677A priority patent/JP2011144201A/ja
Priority to US13/587,752 priority patent/US9089535B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
GBGB0405634.7A 2004-03-12 2004-03-12 Anti-virus therapy for respiratory diseases Ceased GB0405634D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB0405634.7A GB0405634D0 (en) 2004-03-12 2004-03-12 Anti-virus therapy for respiratory diseases
PL05708482T PL1734987T3 (pl) 2004-03-12 2005-03-07 Interferon beta w terapii antywirusowej w przypadku chorób układu oddechowego
JP2007502414A JP4807526B2 (ja) 2004-03-12 2005-03-07 呼吸器疾患の抗ウイルス療法のためのインターフェロン−β
PT05708482T PT1734987E (pt) 2004-03-12 2005-03-07 Interfer†o-beta para terap—utica antivrica de doenãas respiratërias
PCT/GB2005/050031 WO2005087253A2 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases
CA2558212A CA2558212C (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases
AT05708482T ATE466591T1 (de) 2004-03-12 2005-03-07 Interferon-beta zur antiviralen therapie für atemwegserkrankungen
EP05708482A EP1734987B1 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases
DE602005021078T DE602005021078D1 (de) 2004-03-12 2005-03-07 Interferon-beta zur antiviralen therapie für atemwegserkrankungen
HK07104017.4A HK1097181B (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases
ES05708482T ES2343732T3 (es) 2004-03-12 2005-03-07 Interferon beta para la terapia antivirica de enfermedades respiratorias.
CA2787978A CA2787978A1 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases
EP10161661A EP2206512A3 (en) 2004-03-12 2005-03-07 Increase of interferon-beta for anti-virus therapy for respiratory diseases
DK05708482.4T DK1734987T3 (da) 2004-03-12 2005-03-07 Interferon-beta til antivirusbehandling af respiratoriske sygdomme
US11/517,763 US7569216B2 (en) 2004-03-12 2006-09-08 Anti-virus therapy for respiratory diseases
US12/487,563 US8273342B2 (en) 2004-03-12 2009-06-18 Anti-virus therapy for respiratory diseases
JP2011093677A JP2011144201A (ja) 2004-03-12 2011-04-20 呼吸器疾患の抗ウイルス療法のためのインターフェロン−β
US13/587,752 US9089535B2 (en) 2004-03-12 2012-08-16 Anti-virus therapy for respiratory diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0405634.7A GB0405634D0 (en) 2004-03-12 2004-03-12 Anti-virus therapy for respiratory diseases

Publications (1)

Publication Number Publication Date
GB0405634D0 true GB0405634D0 (en) 2004-04-21

Family

ID=32117582

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0405634.7A Ceased GB0405634D0 (en) 2004-03-12 2004-03-12 Anti-virus therapy for respiratory diseases

Country Status (12)

Country Link
US (3) US7569216B2 (enExample)
EP (2) EP2206512A3 (enExample)
JP (2) JP4807526B2 (enExample)
AT (1) ATE466591T1 (enExample)
CA (2) CA2787978A1 (enExample)
DE (1) DE602005021078D1 (enExample)
DK (1) DK1734987T3 (enExample)
ES (1) ES2343732T3 (enExample)
GB (1) GB0405634D0 (enExample)
PL (1) PL1734987T3 (enExample)
PT (1) PT1734987E (enExample)
WO (1) WO2005087253A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US8318423B2 (en) * 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
CA2622016A1 (en) * 2005-09-09 2007-03-15 Imperial Innovations Limited Interferon lambda therapy for treatment of respiratory diseases
EP1940451A4 (en) 2005-09-20 2010-03-17 Univ New York METHOD FOR THE TREATMENT OF LUNG IN DISEASE WITH INTERFERONS
DE102006022877B4 (de) 2006-05-15 2009-01-29 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
GB0713402D0 (en) * 2007-07-11 2007-08-22 Cardiff & Vale Nhs Trust A method of diagnosing a condition using a neural network
CA2707986A1 (en) * 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
WO2010123527A2 (en) * 2008-12-19 2010-10-28 The Regents Of The University Of California Use of epidermal growth factor inhibitors in the treatment of viral infection
WO2011067759A1 (en) * 2009-12-02 2011-06-09 Neetour Medical Ltd. Hemodynamics-based monitoring and evaluation of a respiratory condition
HRP20161158T1 (hr) * 2010-03-12 2016-11-18 Synairgen Research Limited Interferon beta za liječenje bolesti donjeg dišnog sustava izazvane gripom
JP2013537892A (ja) 2010-09-22 2013-10-07 ザ ユニバーシティー オブ メルボルン 新規な免疫賦活法
EP3954714A1 (en) 2014-01-08 2022-02-16 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use
ES3028362T3 (en) * 2017-07-24 2025-06-19 Novavax Inc Methods and compositions for treating respiratory disease
BR112020012360A2 (pt) 2017-12-21 2020-11-24 Ena Therapeutics Pty Ltd compostos otimizados
US20220233643A1 (en) * 2019-02-13 2022-07-28 University Of Florida Research Foundation, Incorporated TARGETING LUNG-RESIDENT TNFR2+ cDC2 (R2D2) SUBPOPULATION TO TREAT ASTHMA
WO2020257870A1 (en) 2019-06-26 2020-12-30 Ena Therapeutics Pty Ltd Novel molecules
KR20230041097A (ko) 2020-07-20 2023-03-23 시네어젠 리서치 리미티드 SARS-CoV-2 감염 환자의 결과를 개선하기 위한 흡입형 인터페론-베타
GB202014114D0 (en) * 2020-09-08 2020-10-21 Synairgen Res Ltd Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
EP4553084A3 (en) * 2020-11-04 2025-11-26 Ethris GmbH Use of ifn-lambda mrna for treating viral infections
CN117545500A (zh) * 2021-01-13 2024-02-09 瑷备恩有限公司 针对呼吸道病毒的预防性施用方法，包括向潜在的呼吸道病毒感染对象施用干扰素β

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596260B1 (en) * 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
WO1995031479A1 (en) * 1994-05-18 1995-11-23 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU780270B2 (en) * 2000-02-23 2005-03-10 Association Francaise Contre Les Myopathies Treatment of immune diseases
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
EP1334128A2 (en) 2000-11-02 2003-08-13 Maxygen Aps New multimeric interferon beta polypeptides
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
WO2003066002A2 (en) 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
EP1575609A4 (en) 2002-10-23 2010-12-15 Zymogenetics L L C METHOD FOR THE TREATMENT OF VIRUS INFECTIONS USING IL-28 AND IL-29
EP2251353B1 (en) 2003-08-07 2013-03-06 ZymoGenetics, Inc. Homogeneous preparations of IL-29
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
CA2558829C (en) 2004-04-02 2014-03-11 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29 cysteine mutants

Also Published As

Publication number Publication date
HK1097181A1 (en) 2007-06-22
US9089535B2 (en) 2015-07-28
PL1734987T3 (pl) 2010-10-29
DK1734987T3 (da) 2010-08-30
DE602005021078D1 (de) 2010-06-17
US8273342B2 (en) 2012-09-25
WO2005087253A2 (en) 2005-09-22
EP1734987A2 (en) 2006-12-27
JP2007528890A (ja) 2007-10-18
US20130209399A1 (en) 2013-08-15
JP2011144201A (ja) 2011-07-28
CA2787978A1 (en) 2005-09-22
JP4807526B2 (ja) 2011-11-02
PT1734987E (pt) 2010-07-06
EP1734987B1 (en) 2010-05-05
CA2558212A1 (en) 2005-09-22
EP2206512A2 (en) 2010-07-14
US20070134763A1 (en) 2007-06-14
ATE466591T1 (de) 2010-05-15
EP2206512A3 (en) 2013-01-09
US20090257980A1 (en) 2009-10-15
ES2343732T3 (es) 2010-08-09
CA2558212C (en) 2012-11-27
WO2005087253A3 (en) 2005-11-24
US7569216B2 (en) 2009-08-04

Similar Documents

Publication Publication Date Title
GB0405634D0 (en) Anti-virus therapy for respiratory diseases
CY1108326T1 (el) ΝΕΟΣ ΣΥΝΔΥΑΣΜΟΣ ΑΝΤΙΧΟΛΙΝΕΡΓΙΚΩΝ ΚΑΙ β ΜΙΜΗΤΙΚΩΝ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΙΑ ΑΝΑΠΝΕΥΣΤΙΚΩΝ ΑΣΘΕΝΕΙΩΝ
UA83813C2 (ru) Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
AP1712A (en) Novel tiotropium-containing inhalation powder
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
GB0127989D0 (en) Medicament dispensing system
DE602005026007D1 (de) Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
MY146628A (en) Novel crystalline anhydride with anticholinergic effect
ATE421325T1 (de) Kombination von methylxanthinverbindungen und steroiden zur behandlung chronischer atemwegserkrankungen
ATE539785T1 (de) Aerosolbildender trockenpulverinhalator
JP2011144201A5 (enExample)
CY1108420T1 (el) Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη
TW200720236A (en) Organic compounds
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
SG149876A1 (en) Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
EP2380569A3 (de) Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen
NO20073909L (no) Forstover-formulering
EA200701077A1 (ru) Применение конъюгатов липидов при лечении заболеваний
WO2011110861A3 (en) Therapy for influenza like illness
MXPA04007294A (es) Composicion para inhalacion.
MXPA04002401A (es) Nuevos medicamentos para inhalacion.
WO2005007134A8 (de) Pulverformulierungen für die inhalation enthaltend ein neues anticholinergikum
Miller Combined inhaled bronchodilators in COPD
IL165574A0 (en) Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases
HK1116096A (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)